Akeso, Inc. (09926.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−48.5x

Market Cap

HKD 91.37B

MomentumView details →

1D Return

+11.45%

YTD Return

−10.44%

RSI (14)

57.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−48.5x

Market Cap

HKD 91.37B

RSI (14)

57.1

MomentumView details →

1D Return

+11.45%

YTD Return

−10.44%

ProfitabilityView details →

Gross Margin

77.88%

Net Margin

−30.43%

EBITDA Margin

−25.81%

ROE (TTM)

−21.19%

ROA (TTM)

−11.09%

Asset Turnover

0.37x

GrowthView details →

Revenue YoY

−5.09%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+52.61%

EPS CAGR 3Y

−100.00%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.53

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

HKD 0.00

Avg Surprise (4Q)

—

Rev Surprise

−23.98%

Capital & dividendView details →

Debt/Equity

0.59x

Current Ratio

4.01x

Quick Ratio

3.62x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

5.91B

Net Income (TTM)

−1.80B

Op. CF (TTM)

−969.59M

Next earningsMar 31, 2027 →

Latest newsMore news →

CStone Pharmaceuticals reported first-half 2026 results with revenue of 1.806 billion yuan, up 27.9% year-on-year, and a net loss attributable to shareholders of 424 million yuan.15h ago

Akeso announced that its self-developed bispecific antibody ivonescimab achieved statistically significant and clinically beneficial positive results in an interim overall survival analysis of the Phase III HARMONi-2 study for first-line treatment of PD-L1-positive non-small cell lung cancer.18h ago

Similar companies

CG Invites Co., Ltd.083790.KQ Innovent Biologics, Inc.01801.HK MedPacto, Inc.235980.KQ iNtRON Biotechnology, Inc.048530.KQ Regeneron Pharmaceuticals, Inc.REGN Sino Biopharmaceutical Limited01177.HK Find similar companies →

Latest newsMore news →

CStone Pharmaceuticals reported first-half 2026 results with revenue of 1.806 billion yuan, up 27.9% year-on-year, and a net loss attributable to shareholders of 424 million yuan.15h ago Akeso announced that its self-developed bispecific antibody ivonescimab achieved statistically significant and clinically beneficial positive results in an interim overall survival analysis of the Phase III HARMONi-2 study for first-line treatment of PD-L1-positive non-small cell lung cancer.18h ago Akeso Inc. announced positive overall survival results from the Phase III HARMONi-2 study, showing ivonescimab monotherapy significantly improved OS versus pembrolizumab in PD-L1-positive advanced NSCLC.2d ago